SUMY ANTHONY: Open Payments
NPI 1003240862 · AURORA, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$912 in 31 payments from 10 companies in 2025. Trend: 2023 $1,243 · 2024 $1,156 · 2025 $912
Food & beverage: $912
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $187 |
| Janssen Biotech, Inc. | 3 | $143 |
| Exelixis Inc. | 3 | $123 |
| TerSera Therapeutics LLC | 5 | $119 |
| Eisai Inc. | 4 | $93 |
| Merck Sharp & Dohme LLC | 3 | $85 |
| Genmab U.S., Inc. | 2 | $59 |
| Astellas Pharma US Inc | 2 | $57 |
| SOBI, INC | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
Products named: Trodelvy, CABOMETYX, Zoladex, TALVEY, Lenvima, KEYTRUDA, Tivdak, Vyloy.
Industry payments across CO — which companies pay providers there.
